Authors contributed equally to the work.
Clinical relevance of SKP2 alterations in metastatic melanoma
Version of Record online: 21 OCT 2010
© 2010 John Wiley & Sons A/S
Pigment Cell & Melanoma Research
Volume 24, Issue 1, pages 197–206, February 2011
How to Cite
Rose, A. E., Wang, G., Hanniford, D., Monni, S., Tu, T., Shapiro, R. L., Berman, R. S., Pavlick, A. C., Pagano, M., Darvishian, F., Mazumdar, M., Hernando, E. and Osman, I. (2011), Clinical relevance of SKP2 alterations in metastatic melanoma. Pigment Cell & Melanoma Research, 24: 197–206. doi: 10.1111/j.1755-148X.2010.00784.x
- Issue online: 13 JAN 2011
- Version of Record online: 21 OCT 2010
- Accepted manuscript online: 30 SEP 2010 04:44AM EST
- PUBLICATION DATA Received 6 May 2010, revised and accepted for publication 24 September 2010, published online 30 September 2010
Figure S1. (A) Evidence of increased DNA copy number at the SKP2 locus (5p13.2) in 7 melanoma cell lines (out of 18 assessed) identified using SNP array. (B) Cytoband view showing the location of the amplifications in the metastatic melanoma cell lines.
Table S1. Segmentation analysis of copy number alterations (N = 7) identified at the 5p13.2 locus using SNP array in melanoma cell lines (N = 18) and melanocyte controls (n = 4).
Table S2. Primers utilized for genomic qPCR of SKP2 (A) and sequencing of FZR and SKP2 (B).
|PCMR_784_sm_FigureS1.tif||466K||Supporting info item|
|PCMR_784_sm_TableS1.doc||29K||Supporting info item|
|PCMR_784_sm_TableS2.doc||42K||Supporting info item|
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.